Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 79 of 5804
-
New combo therapy aims to boost survival in esophageal cancer patients
Disease control Recruiting nowThe primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo shot CagriSema aims for major weight loss in 3,400 adults
Disease control OngoingThis study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Triple-Drug cocktail aims to boost remission in acute myeloid leukemia
Disease control CompletedThis is a single arm study to evaluate the safety and efficiency of azacitidine (AZA) combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia. Azacitidine, venetoclax and ATRA, may stop the growth of cancer cells, either by demethylation, by p…
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Aggressive blood pressure control may fight Alzheimer's in the brain
Disease control OngoingThe purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for m…
Phase: PHASE2 • Sponsor: Rong Zhang • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Promising new drug cocktails aim to control multiple myeloma longer
Disease control Recruiting nowThe purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: targeted drug combo enters phase 3
Disease control Recruiting nowThis study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A sid…
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Catheter-Directed Clot-Busting may offer safer option for dangerous blood clots in the lungs
Disease control CompletedBackground: Intermediate-high risk acute pulmonary embolism (PE) remains associated with substantial mortality despite standard anticoagulation therapy. Previous efforts to decrease mortality in these patients via administration of systemic thrombolysis have failed due to an incr…
Phase: PHASE4 • Sponsor: Faculty Hospital Kralovske Vinohrady • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy aims to tame rare metabolic disorder
Disease control OngoingThe primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for blood cancer: Triple-Drug attack shows promise
Disease control OngoingThe purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New immunotherapy combo aims to outperform standard lung cancer treatment
Disease control OngoingThe primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small …
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Obesity drug tirzepatide aims to cut heart attacks and deaths in massive trial
Disease control OngoingThis study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a new drug slow Alzheimer's? large trial underway
Disease control OngoingThe reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill shows promise in slowing deadly lung disease
Disease control CompletedThis study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older. If they already take nintedanib or pirfenidone for their IPF, they can continue treatment throughout the study. The purpose of thi…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug aims to stop breast cancer recurrence in High-Risk patients
Disease control OngoingThe main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken en…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Promising new combo aims to boost survival in kids with relapsed leukemia
Disease control Recruiting nowA study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive addition…
Phase: PHASE3 • Sponsor: PedAL BCU, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Pioneering fetal brain surgery aims to prevent newborn heart failure
Disease control OngoingThis is a prospective, single-arm non-randomized interventional study of fetuses to assess the safety and efficacy of fetal embolization of Vein of Galen Malformation (VOGM). Subjects will receive a one-time study intervention of fetal embolization. Follow-up assessments will be …
Phase: NA • Sponsor: Darren Orbach • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New COVID-19 vaccine trial aims to protect kids from latest variants
⭐️ VACCINE ⭐️ OngoingThe purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on ag…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
Immune cell therapy takes on hard-to-treat lymphoma in major trial
Disease control OngoingThe goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New CAR T-Cell therapy shows promise for kids with tough leukemia
Disease control Recruiting nowThis study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
Phase: PHASE1, PHASE2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for myeloma: phase 3 trial launches for mezigdomide combo
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC